Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates
Alvotech (ALVO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.35 per share a year ago.
Alvotech: Improving Fundamentals Signal A Potential Bottom For This Biosimilar Player
Alvotech is rated a speculative buy with a $4 price target, implying over 12% upside from current levels. ALVO posted double-digit revenue growth and positive GAAP profitability in FY 2025, but remains reliant on debt and minimal operating cash flow. 2026 catalysts include FDA approvals for key biosimilars and continued commercialization, with Selarsdi and AVT02 as major growth levers.
Alvotech: Why FDA Delays Don't Break The Bull Case
Alvotech remains my favorite in the biosimilars market, which is expected to reach $151.6 billion by 2033. It already has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. Even though it received three CRLs in Q4, Alvotech expects its revenue to be between $650 million and $700 million in 2026, up 37.2% from 2024.
Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript
Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript
Alvotech (ALVO) Q3 2025 Earnings Call Transcript
Alvotech ( ALVO ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Benedikt Stefansson - VP of Investor Relations and Global Communications Robert Wessman - CEO, Founder & Executive Chairman Joseph McClellan - Chief Scientific & Technical Officer Linda Jonsdottir - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Thibault Boutherin - Morgan Stanley, Research Division Arvid Necander - DNB Carnegie, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Alvotech Q3 2025 Earnings Conference Call.
New Strong Sell Stocks for Nov. 13
AMRK, ALVO and GPK have been added to the Zacks Rank #5 (Strong Sell) List on Nov. 13, 2025.
Alvotech (ALVO) Reports Q3 Loss, Misses Revenue Estimates
Alvotech (ALVO) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.05. This compares to earnings of $0.19 per share a year ago.
Alvotech: Promising Vertically Integrated Biosimilar Platform
Alvotech is a vertically integrated biosimilar pure-play. In my view, this makes it a relatively safer bet compared to other, more speculative biotechs. ALVO plans on launching adalimumab and ustekinumab globally, with EU approval for aflibercept. Its recent partnerships will also expand its reach and share R&D costs. This includes a promising preclinical biosimilar for Keytruda.
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.
Alvotech (ALVO) Q2 Earnings and Revenues Beat Estimates
Alvotech (ALVO) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to earnings of $0.28 per share a year ago.
Wall Street Analysts Think Alvotech (ALVO) Could Surge 102.31%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 102.3% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
